Keywords: lotemax, phiii, studies, completed, pharmos, its, phase

Lotemax PhIII Studies Completed

Article | 25 March 1996

Print This

- Pharmos has completed its Phase III studies of Lotemax (loteprednol etabonate), its site-specific steroid for seasonal allergic conjunctivitis.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in